TCS CEO corrects three major Nashik facts: Nida Khan was not HR head, unit not shut, no POSH complaints on record
Read More Pharma Industry News Johnson & Johnson grabs RIPTAC cancer tech in $3bn Halda Therapeutics deal Johnson & Johnson acquires Halda Therapeutics for $3.05B, expanding its oncology portfolio with precision prostate cancer treatments. Find out what’s next. bySrinathNovember 19, 2025